Cleveland BioLabs to Present at BARDA and NIAID Sponsored Symposium on
Development of Radiation Medical Countermeasures
BUFFALO, N.Y., Jan. 24, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc.
(Nasdaq:CBLI) today announced that the Company was invited to present at a
symposium hosted by the Biomedical Advanced Research and Development Authority
(BARDA) and National Institute of Allergy and Infectious Diseases (NIAID),
part of the National Institutes of Health. The symposium, titled "Development
of Radiation Medical Countermeasures for Licensure: Lessons Learned & Paths
Forward" will include select product developers like CBLI, as well as U.S.
government representatives of BARDA, NIAID, the U.S. Food and Drug
Administration, the Department of Defense and the Centers for Disease Control
The primary aim of the two day meeting being held on January 24 and 25, is to
share data and serve as a forum regarding the challenges of medical
countermeasure product development to mitigate the effects of acute radiation
syndrome (ARS), and/or the delayed effects of acute radiation exposure
(DEARE). The symposium's goal is to harmonize the current understanding of
animal models for ARS and DEARE, and allow for candid discussions between the
regulatory authorities and the broader product development community in order
to enhance future development.
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a clinical-stage biotechnology company leveraging
deep mechanistic understanding of the cell death process, apoptosis, to
develop a robust pipeline of compounds primarily focused on oncology
applications and mitigation of radiation injury. The Company's lead compound
is being developed as both a radiation countermeasure and a cancer treatment.
The Company has two operating subsidiaries, Incuron, LLC, and Panacela Labs,
Inc., and strategic relationships with the Cleveland Clinic, Roswell Park
Cancer Institute, the Children's Cancer Institute Australia and the Armed
Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs,
Inc., please visit the Company's website at http://www.cbiolabs.com.
The Cleveland BioLabs, Inc. logo is available at
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of this
press release, and involve certain risks and uncertainties. The Company's
actual results could differ materially from those anticipated in these
forward-looking statements as a result of various factors.
These factors include, among others, the Company's history of operating losses
and the potential for future losses, which may lead the Company to not be able
to continue as a going concern; the Company's need for substantial additional
financing to meet its business objectives; the potential for the loss of
funding from the Company's R&D grants and contracts and its ability to win
additional funding under such grants and contracts; the Company's failure to
successfully and timely develop new products; the risks inherent in the early
stages of drug development and in conducting clinical trials; the Company's
inability to obtain regulatory approval in a timely manner or at all; the
Company's collaborative relationships and the financial risks related thereto;
the Company's ability to comply with its obligations under license agreements;
the potential for significant product liability claims; and the Company's
ability to comply with various safety, environmental and other governmental
regulations. Some of these factors could cause future results to materially
differ from the recent results or those projected in forward-looking
statements.See also the "Risk Factors" and "Forward-Looking Statements"
described in the Company's periodic filings with the Securities and Exchange
Rachel Levine, Vice President, Investor Relations
Cleveland BioLabs, Inc.
T: (646) 284-9439
Cleveland BioLabs, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.